Trial to assess the effect of blood pressure lowering drug (Dexmedetomidine) to control blood loss during spine surgery

Effect Of Dexmedetomidine Infusion On Intraoperative Hemodynamics And Anesthetic Requirements In Patients Undergoing Elective Spine Surgery: A Prospective Randomized Control Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/05/042376

Enrollment

Registered

2022-05-04

Start date

Unknown

Completion date

Unknown

Last updated

2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Control Intervention1: Dexmedetomidine - GROUP A: LOADING DOSE - 1 MCG/KG/HOUR IV FOR 10 MINUTES AND MAINTENANCE DOSE - 0.2 - 0.7 MCG/KG/HOUR CONTINOUS Control Intervention2: Dexmedetomidine - GROUP

Eligibility

Inclusion criteria

Inclusion criteria: All patients giving consent Elective spinal surgeries only Patients aged >18 years & Patients of either sex ASA Grade I & II

Exclusion criteria

Exclusion criteria: PREGNANT PATIENTS PATIENTS SUFFERING FROM HYPERTENSION UNCONTROLLED DIABETES MELLITUS MORBID OBESITY COPD SEVERE RENAL, HEPATIC, CARDIAC DYSFUNCTION EMERGENCY SPINE SURGERY HISTORY OF DRUG ABUSE

Design outcomes

Primary

Measure	Time frame
HYPOTENSION BLOOD LOSS ANALGESIA USETimepoint: HYPOTENSION - EVERY 30 MINUTES BLOOD LOSS - EVERY 30 MINUTES ANALGESIA USE - EVERY 30 MINUTES	—

Secondary

Measure	Time frame
ANALGESIA REQUIREMENTTimepoint: ANALGESIA USE - EVERY 1 HOUR	—

Countries

India

Contacts

Public ContactANJALI SATHISH

PADMASREE D Y PATIL MEDICAL COLLEGE

varsha.vyas011@gmai.com9819583232

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026